Acute toxicity information in early safety assessment

This article covers what acute toxicity information is used for, where it now comes from, and how the pharmaceutical framework differs from the acute toxicity testing done on industrial chemicals. It is written for people commissioning nonclinical work in the United States.

What the guidance actually says

Two statements in the guidance govern this subject, and both differ from how acute toxicity is often described. The first is that lethality should not be an intended endpoint in studies assessing acute toxicity.^[S1] The second is that where acute toxicity information is available from any study, separate single-dose studies are not recommended.^[S1] Taken together they mean that a standalone acute toxicity study whose purpose is to find a lethal dose is not what the current framework asks for. What is wanted is information about the effects of a single high exposure, and that information is normally obtained from the dose-escalation or short-duration dose-ranging studies that establish the maximum tolerated dose in the species used for general toxicology.^[S1]

Pharmaceuticals and industrial chemicals are tested for different reasons

Acute toxicity testing exists in two separate worlds and the methods do not transfer between them. For industrial chemicals, standardized test guidelines produce data used to classify a substance for labelling and workplace safety.^[S4] For pharmaceuticals, the question is what a single high exposure does in the species used for the development programme, as an input to setting doses for the studies that follow.^[S1] A laboratory that offers acute oral toxicity testing to the chemical guidelines is offering something different from what a drug programme needs, even though both are called acute toxicity testing. Confirm which framework a quoted study is designed against.

What is measured

Clinical signs and target organs

Animals are observed for clinical signs, body weight change and food consumption, with the timing of onset and of recovery recorded. Necropsy and histopathology at the end of the observation period identify which organs were affected. Those organs become the ones monitored most closely in the repeat-dose studies that follow, which is the main practical value of this information.

The maximum tolerated dose

Older practice required calculation of the dose lethal to half the animals tested. That is no longer what is asked for. The guidance states that lethality should not be an intended endpoint,^[S1] and it frames the change in terms of reducing animal use in accordance with the principles of replacement, reduction and refinement.^[S2] The quantity now used is the maximum tolerated dose, meaning the highest dose at which toxicity is present but tolerated, established through dose escalation.^[S1] Terms describing an approximate lethal dose belong to the chemical testing framework and do not appear in the pharmaceutical guidance.

Relationship to repeat-dose studies

What each answers

A single exposure answers what happens acutely at a high dose. Repeated exposure over weeks to months answers what accumulates, what appears only after prolonged dosing, and whether findings reverse when dosing stops. The required duration of the repeat-dose studies is tied to the duration of the clinical trial they support, and those studies are conducted in two mammalian species, one of them a non-rodent.^[S3]

Setting doses for what follows

Acute toxicity information does not establish safety on its own. Its function is to set the doses for the repeat-dose studies: the maximum tolerated dose defines the upper end of the range, and the pattern of findings indicates what to monitor. Getting this wrong is expensive in a specific way. A high dose set too low produces a study with no findings and no established margin, and a high dose set too high produces a study that has to be repeated.

Design points

Species and route

The two-species requirement is often attached to acute toxicity, and that is a misreading. The guidance describes using two mammalian species by both the clinical and a parenteral route as what was historically done in single-dose studies, and then states that the information can instead be obtained from dose-escalation or short-duration dose-ranging studies in the species used for general toxicology.^[S1] The two-species requirement, with one non-rodent, attaches to the repeat-dose studies.^[S3] On route, the clinical route is the one that matters, because exposure by a different route may not correspond.

Which guidance applies

In the United States the applicable document is the same international guideline, issued by the Food and Drug Administration as its own guidance for industry in January 2010.^[S1] There is no separate national standard to satisfy alongside it. Because the guideline was agreed across regions, a study designed against it is generally acceptable in the other regions that adopted it, although each regulator publishes additional guidance of its own that a global programme has to check.

What to check when placing this work

GLP, stated accurately

Good laboratory practice applies to an individual study rather than to a facility, so the question is not whether a laboratory is compliant but whether this study will be conducted under the regulation.^[S5] The application to begin clinical work requires, for each nonclinical study, a statement that it was conducted in compliance, or a brief statement of the reason if it was not.^[S6] That means a non-compliant study is not automatically unusable, but the position has to be declared. Two things are worth verifying rather than accepting: that an independent quality assurance unit exists and what it does,^[S5] and the laboratory inspection history, which the agency publishes and updates weekly.^[S8]

Animal welfare credentials, read correctly

The guidance itself frames the move away from lethality endpoints in terms of reducing animal use,^[S2] so a laboratory that proposes a design obtaining the required information from fewer animals is working with the guidance rather than around it. On accreditation, AAALAC International states plainly that it is not a regulatory body and does not make or enforce regulations; its accreditation is a voluntary evaluation of an animal care and use programme, reassessed every three years.^[S7] It is useful information about the programme. It is not a regulatory approval, and it says nothing about whether a given study will be conducted under the good laboratory practice regulation.^[S5]

About this article

This is an independent editorial article for people who commission nonclinical work in the United States. It describes what the current guidance says, which differs in places from descriptions of acute toxicity testing still in circulation. Guidance describes the agency current thinking and is not binding; an alternative approach may be used if it satisfies the applicable regulations. This site does not recommend any laboratory. Last reviewed: September 3, 2026.

References

1. FDA — ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, January 2010 (Revision 1)、Chapter IV Acute Toxicity Studies. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization (accessed 2026-09-03)
2. FDA — ICH M3(R2)、Statement regarding the reduction in the number of animals used. https://www.fda.gov/media/71542/download (accessed 2026-09-03)
3. FDA — ICH M3(R2)、Description regarding animal species for repeated-dose toxicity studies. https://www.fda.gov/media/71542/download (accessed 2026-09-03)
4. OECD — Test No. 420: Acute Oral Toxicity, Fixed Dose Procedure、Test No. 423: Acute Toxic Class Method、Test No. 425: Up-and-Down Procedure（OECD Guidelines for the Testing of Chemicals）. https://www.oecd.org/en/publications/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en.html (accessed 2026-09-03)
5. 21 CFR Part 58 — Good Laboratory Practice for Nonclinical Laboratory Studies (§58.1 scope; §58.35 quality assurance unit). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-58 (accessed 2026-09-03)
6. 21 CFR 312.23(a)(8)(iii) — For each non-clinical study, a statement of GLP compliance—or, in cases of non-compliance, a brief explanation of the reason—is required. https://www.govinfo.gov/content/pkg/CFR-2023-title21-vol5/xml/CFR-2023-title21-vol5-sec312-23.xml (accessed 2026-09-03)
7. AAALAC International — Accreditation Program FAQs. https://www.aaalac.org/accreditation-program/faqs/ (accessed 2026-09-03)
8. FDA — Inspection Classification Database. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-classification-database (accessed 2026-09-03)